A Phase 3 interventional study of Lamictal in Epilepsy, sponsored by GlaxoSmithKline. Completed at 14 sites in 2 countries. Open to participants aged 2 Years to 15 Years. Per ClinicalTrials.gov, last updated 2017-03-08.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing lamotrigine in Epilepsy — 2 open to participants now, 2 under way, none of them phase 3. Lamotrigine · Epilepsy.
Among the 36 studies testing lamotrigine in Epilepsy, this one is the 34th largest by enrollment, is one of 3 that started in 2011, is one of 12 in phase 3, and was the 24th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →2 of the 36 studies testing lamotrigine in Epilepsy are open now. Recruiting first, the newest first:
Assiut University
Ages 2–12 · Healthy volunteers
National Taiwan University Hospital
Ages 20+
Lamotrigine: first FDA approval 1994 (LAMICTAL). What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 2 Years to 15 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 76 across the 36 interventional studies. Of the 32 that completed or were terminated, 14 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 36 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
54 studies in Epilepsy by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 53 finished, 23 (43%) have results posted.
Among the 54 studies in Epilepsy by GlaxoSmithKline, this one is the 32nd largest by enrollment of the 39 interventional ones that give a count, is one of 10 that started in 2011, is one of 18 in phase 3, and was the 33rd registered.
GlaxoSmithKline’s Epilepsy studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 36 studies testing lamotrigine in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 54 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multi-center, uncontrolled, open-label study to evaluate the efficacy and safety of lamotrigine monotherapy on newly diagnosed typical absence seizure in children and adolescents in Japan and South Korea.
The study period is composed the baseline, fixed escalation phase, escalation phase, maintenance phase, taper phase, and post study examination. During the fixed escalation phase, the investigational product is administered at 0.3 mg/kg/day for 2 weeks (Week 1 to 2), followed by 0.6 mg/kg/day for 2 weeks (Week 3 to 4). Subjects thereafter visit the clinic once every 1 to 2 weeks during the escalation phase to increase the dose by 0.6 mg/kg/day up to a maximum of 10.2 mg/kg/day or 400 mg/day (whichever was less) until patients are confirmed to be seizure-free by HV tests for clinical signs. After seizure free is confirmed by HV-clinical signs, the dose is increased by one level and HV-EEG (electroencephalography) test (first test) is assessed at the next visit. If seizure free is observed by HV-EEG, the same dose is administered. Thereafter, HV-EEG (second test) is assessed at the next visit and if seizure free is confirmed again, the subjects enter the 12-week maintenance phase. During the maintenance phase, patients visit the clinic once every 4 weeks. The dose can be adjusted as necessary within the range of 1.2 to 10.2 mg/kg/day or 400 mg/day (whichever was less) taking into account the status of seizures and the safety. The investigational product is administered once daily (in the evening). However, if the number of tablets is large, twice-daily administration (in the morning and evening) is also allowed. After the completion of maintenance phase, subjects who have responded to lamotrigine without tolerability issues are eligible to enter the extension phase of the study if clinically indicated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of typical absence seizures is established by at least one of two 4-minute hyperventilation tests as supported by clinical signs and EEG findings.
The following criteria will be used to define a typical absence seizure on the EEG: a discharge of generalized spike-and-wave or multiple spike-and-wave activity lasting ≥3 seconds during the awake state. The frequency of the spike-and-wave should be between 2.5-4.5 Hz.
Age (at the time of obtaining consent):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No comparison
Drug: Lamictal
No comparison
Number of Participants Who Were Seizure Free as Confirmed by Hyperventilation (HV)-Electroencephalography (EEG) at the End of the Maintenance Phase (MP)
EEG is a diagnostic test for epilepsy. The EEG machine records the brain's electrical activity as a series of waveforms. HV is an activation technique used to provoke seizures during an EEG recording. An approximately 30-minute EEG with HV was performed on participants in a supine position. In the HV test, participants breathed through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute) for 4 continuous minutes using a pin-wheel provided to them.
Time frame: Week 12 of the Maintenance Phase (up to Study Week 50)
Number of Participants Who Were Seizure Free as Confirmed by HV-EEG at Two Consecutive Visits in the Escalation Phase (EP)
EEG is a diagnostic test for epilepsy. The EEG machine records the brain's electrical activity as a series of waveforms. HV is an activation technique used to provoke seizures during an EEG recording. An approximately 30-minute EEG with HV was performed on participants in a supine position. In the HV test, participants breathed through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute ) for 4 continuous minutes using a pin-wheel provided to them.
Time frame: Up to Study Week 49
Number of Participants Who Were Seizure Free as Confirmed by HV-clinical Signs at Each Dose During the Escalation Phase
HV is an activation technique used to provoke seizures. Participants were instructed to breathe through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute) for 4 continuous minutes while sitting using a pin-wheel and were observed for clinical signs of seizures like impairment of consciousness; staring; eye enrollment; eye blinking; chewing movements; hand movement; other automatisms; atonic, tonic, clonic components; autonomic components; or any other signs. During the Escalation Phase, HV-clinical signs were assessed to confirm a status of seizure free. Only participants data available at the analysis time point were analyzed (represented as n=X, X, X in category title).
Time frame: Up to Study Week 49
Number of Participants Who Were Seizure Free as Confirmed by HV-clinical Signs During Week 4 and Week 8 of the Maintenance Phase
HV is an activation technique used to provoke seizures. Participants were instructed to breathe through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute) for 4 continuous minutes while sitting using a pin-wheel and were observed for clinical signs of seizures like impairment of consciousness; staring; eye enrollment; eye blinking; chewing movements; hand movement; other automatisms; atonic, tonic, clonic components; autonomic components; or any other signs. During the Maintenace Phase, HV-clinical signs were assessed at Visit 1 (Week 4) and Visit 2 (Week 4).
Time frame: Week 4 and Week 8 of the Maintenance Phase (up to Study Weeks 42 and 46, respectively)
Number of Participants Who Were Seizure Free as Confirmed by HV-EEG at Each Assessment Point in the Extension Phase (ExP)
EEG is a diagnostic test for epilepsy. The EEG machine records the brain's electrical activity as a series of waveforms. HV is an activation technique used to provoke seizures during an EEG recording. An approximately 30-minute EEG with HV was performed on participants in a supine position. In the HV test, participants breathed through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute ) for 4 continuous minutes using a pin-wheel provided to them. Only participants data available at the analysis time point were analyzed (represented as n=X, X, X in category title).
Time frame: Extension Week 12 (Extension Visit 1 [Ext-V1]), every 24 weeks after Ext-V1 and until withdrawal
Number of Participants Who Were Seizure Free as Confirmed by HV-clinical Signs at Each Assessment Point in the Extension Phase (ExP)
HV is an activation technique used to provoke seizures. Participants were instructed to breathe through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute) for 4 continuous minutes while sitting using a pin-wheel and were observed for clinical signs of seizures like impairment of consciousness; staring; eye enrollment; eye blinking; chewing movements; hand movement; other automatisms; atonic, tonic, clonic components; autonomic components; or any other signs. During the ExP, HV-clinical signs were assessed to confirm a status of seizure free. Only participants data available at the analysis time point were analyzed (represented as n=X, X, X in category title).
Time frame: Extension Week 24 (Extension Visit 2 [Ext-V2], every 24 weeks after the Ext-V2 and until withdrawal
Number of Days With Seizure Episodes Per Week in the Main Study Phase (Fixed Escalation Phase [FEP], Escalation Phase [EP], Maintenance Phase [MP]), and FEP+EP+MP)
Participants were asked to record the seizure codes, seizure duration, and their physical condition in a diary provided. Only participants data available at the analysis time point were analyzed (represented as n=X, X, X in category title)
Time frame: Up to Study Week 50
Number of Days With Seizure Episodes Per Week in the Extension Phase (ExP) Overall
Participants were asked to record the seizure codes, seizure duration, and their physical condition in a diary provided.
Time frame: Extension Week 12 (Extension Visit 1 [Ext-V1], every 12 week after Ext-V1 and until withdrawal
Participants with newly diagnosed and untreated typical absence seizure; aged 2-15 years in Japan, 2-12 years in South Korea at the time of obtaining consent; weighing at least 7 kilograms (kg); without partial seizure or generalized seizures other than typical absence; and without a history of rash associated with other treatment were enrolled.
| Milestone | Lamotrigine |
|---|---|
| Started | 20 |
| Completed | 6 |
| Not completed | 14 |
| Withdrew: Adverse event | 6 |
| Withdrew: Lack of efficacy | 2 |
| Withdrew: Met protocol-defined stopping criteria | 4 |
| Withdrew: Physician decision | 1 |
| Withdrew: Withdrawal by subject | 1 |
EEG is a diagnostic test for epilepsy. The EEG machine records the brain's electrical activity as a series of waveforms. HV is an activation technique used to provoke seizures during an EEG recording. An approximately 30-minute EEG with HV was performed on participants in a supine position. In the HV test, participants breathed through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute) for 4 continuous minutes using a pin-wheel provided to them.
| Participants | Lamotrigine |
|---|---|
| Number of Participants Who Were Seizure Free as Confirmed by Hyperventilation (HV)-Electroencephalography (EEG) at the End of the Maintenance Phase (MP) | 7 |
EEG is a diagnostic test for epilepsy. The EEG machine records the brain's electrical activity as a series of waveforms. HV is an activation technique used to provoke seizures during an EEG recording. An approximately 30-minute EEG with HV was performed on participants in a supine position. In the HV test, participants breathed through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute ) for 4 continuous minutes using a pin-wheel provided to them.
| Participants | Lamotrigine |
|---|---|
| Number of Participants Who Were Seizure Free as Confirmed by HV-EEG at Two Consecutive Visits in the Escalation Phase (EP) | 8 |
HV is an activation technique used to provoke seizures. Participants were instructed to breathe through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute) for 4 continuous minutes while sitting using a pin-wheel and were observed for clinical signs of seizures like impairment of consciousness; staring; eye enrollment; eye blinking; chewing movements; hand movement; other automatisms; atonic, tonic, clonic components; autonomic components; or any other signs. During the Escalation Phase, HV-clinical signs were assessed to confirm a status of seizure free. Only participants data available at the analysis time point were analyzed (represented as n=X, X, X in category title).
| Participants | Lamotrigine |
|---|---|
| 0.6 mg/kg, n=17 | 1 |
| 1.2 mg/kg, n=17 | 1 |
| 1.8 mg/kg, n=16 | 2 |
| 2.4 mg/kg, n=16 | 2 |
| 3.0 mg/kg, n=16 | 2 |
| 3.6 mg/kg, n=15 | 1 |
| 4.2 mg/kg, n=15 | 0 |
| 4.8 mg/kg, n=14 | 4 |
| 5.4 mg/kg, n=14 | 1 |
| 6.0 mg/kg, n=11 | 1 |
| 6.6 mg/kg, n=11 | 0 |
| 7.2 mg/kg, n=9 | 3 |
| 7.8 mg/kg, n=9 | 0 |
| 8.4 mg/kg, n=6 | 2 |
| 9.0 mg/kg, n=6 | 1 |
| 9.6 mg/kg, n=1 | 1 |
HV is an activation technique used to provoke seizures. Participants were instructed to breathe through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute) for 4 continuous minutes while sitting using a pin-wheel and were observed for clinical signs of seizures like impairment of consciousness; staring; eye enrollment; eye blinking; chewing movements; hand movement; other automatisms; atonic, tonic, clonic components; autonomic components; or any other signs. During the Maintenace Phase, HV-clinical signs were assessed at Visit 1 (Week 4) and Visit 2 (Week 4).
| Participants | Lamotrigine |
|---|---|
| Week 4 | 7 |
| Week 8 | 7 |
EEG is a diagnostic test for epilepsy. The EEG machine records the brain's electrical activity as a series of waveforms. HV is an activation technique used to provoke seizures during an EEG recording. An approximately 30-minute EEG with HV was performed on participants in a supine position. In the HV test, participants breathed through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute ) for 4 continuous minutes using a pin-wheel provided to them. Only participants data available at the analysis time point were analyzed (represented as n=X, X, X in category title).
| Participants | Lamotrigine |
|---|---|
| Extension Week 12, n=7 | 6 ± 1.568 |
| Extension Week 36, n=7 | 5 ± 2.114 |
| Extension Week 60, n=7 | 6 ± 0.161 |
| Extension Week 84, n=6 | 6 ± 2.197 |
| Extension Week 108, n=6 | 6 |
| Extension Week 132, n=6 | 6 |
| Extension Week 156, n=2 | 2 |
HV is an activation technique used to provoke seizures. Participants were instructed to breathe through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute) for 4 continuous minutes while sitting using a pin-wheel and were observed for clinical signs of seizures like impairment of consciousness; staring; eye enrollment; eye blinking; chewing movements; hand movement; other automatisms; atonic, tonic, clonic components; autonomic components; or any other signs. During the ExP, HV-clinical signs were assessed to confirm a status of seizure free. Only participants data available at the analysis time point were analyzed (represented as n=X, X, X in category title).
| Participants | Lamotrigine |
|---|---|
| Extension Week 24, n=7 | 5 |
| Extension Week 48, n=7 | 6 |
| Extension Week 72, n=7 | 5 |
| Extension Week 96, n=6 | 6 |
| Extension Week 120, n=6 | 5 |
| Extension Week 144, n=4 | 2 |
| Extension Week 168, n=1 | 1 |
Participants were asked to record the seizure codes, seizure duration, and their physical condition in a diary provided. Only participants data available at the analysis time point were analyzed (represented as n=X, X, X in category title)
| Days | Lamotrigine |
|---|---|
| Fixed Escalation Phase, n=20 | 4.93 ± 1.488 |
| Escalation Phase, n=17 | 2.60 ± 2.060 |
| Maintenance Phase, n=8 | 0.06 ± 0.161 |
| FEP+EP+MP, n=20 | 2.98 ± 1.976 |
Participants were asked to record the seizure codes, seizure duration, and their physical condition in a diary provided.
| Days | Lamotrigine |
|---|---|
| Number of Days With Seizure Episodes Per Week in the Extension Phase (ExP) Overall | 0.03 ± 0.048 |
Collected over Serious adverse events (SAEs) and non-serious AEs were collected from study medication start until the end of treatment (up to Study Week 50) (EP, MP, and ExP).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lamotrigine | — | 0/20 (0%) | 17/20 (85%) |
| Event | Lamotrigine |
|---|---|
| NasopharyngitisInfections and infestations | 7/20 |
| RashSkin and subcutaneous tissue disorders | 6/20 |
| BronchitisInfections and infestations | 5/20 |
| InfluenzaInfections and infestations | 5/20 |
| HeadacheNervous system disorders | 4/20 |
| Upper respiratory tract infectionInfections and infestations | 3/20 |
| Arthropod stingInjury, poisoning and procedural complications | 3/20 |
| PharyngitisInfections and infestations | 2/20 |
| VaricellaInfections and infestations | 2/20 |
| ConjunctivitisInfections and infestations | 2/20 |
| Age, Continuous(Years) | Lamotrigine |
|---|---|
| Mean | 7.7 ± 1.95 |
| Sex: Female, Male(Participants) | Lamotrigine |
|---|---|
| Female | 13 |
| Male | 7 |
| Race/Ethnicity, Customized(participants) | Lamotrigine |
|---|---|
| East Asian Heritage | 3 |
| Japanese Heritage | 16 |
| South East Asian Heritage | 1 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Sep 2011, a primary completion of Feb 2014 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lamotrigine